Month: May 2024

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) — Evercel, Inc. [OTC EXPERT MARKET: EVRC] Evercel, Inc. wishes to clarify its prior press release of February 20, 2024 regarding its Plan of Liquidation and Dissolution. Evercel’s decision to place Evercel’s assets into a liquidating trust has no impact on ZAGG or its operations. Evercel is a passive and minority investor in ZAGG. ZAGG is solely managed by CoronaPark, and has been since CoronaPark took ZAGG private in 2021. The decision of Evercel to place its assets in a liquidating trust, including its minority interest in ZAGG, is solely an action that is consistent with Evercel’s previously disclosed intentions to return any cash it receives from its legacy investments to Evercel shareholders. This action has nothing to do with ZAGG or its business. Cautionary Statement Regarding...

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $160 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 12,972,972 shares of common stock at the offering price. The offering is expected to close on May 21, 2024, subject...

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association (“EHA”) Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online. ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in adult patients with primary Immune Thrombocytopenia (“ITP”) who have received at least one prior line of standard therapy (NCT05029635). In 188 patients randomized to receive oral sovleplenib or placebo, sovleplenib...

VANCOUVER, British Columbia, May 16, 2024 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announced today it will report its financial results for the second quarter ended March 31, 2024 on Thursday, May 23, 2024 after market close. The financial statements and MD&A will be available on SEDAR+ at www.sedarplus.ca and on the Company’s website in the late evening Vancouver time. The Company has scheduled a conference call to discuss the results for Q2 2024 and business outlook on Friday, May 24, 2024 at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). Brent Charleton, Chief Executive Officer and Dylan Murray, Chief Financial Officer will present EnWave’s results and host a question and answer period. Conference Call Details:Date: May 24, 2024Time: 7:00am PST / 10:00am...

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue (ERAS-0015) and...

Sets the Record Straight on Economou’s Campaign Genco Continues Executing on the Comprehensive Value Strategy It Initiated in 2021 Shareholders Should Still Get Their Votes In “FOR” the Re-Election of Genco’s Seven Highly Qualified Director Nominees NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”) the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today issued the following statement regarding George Economou’s withdrawal of the nomination of Robert Pons for election to the Genco Board of Directors. Genco issued the following statement: We are pleased that George Economou has withdrawn from the proxy fight that he started. We note that to the very end, Economou continued to disseminate statements about Genco,...

TORONTO, May 16, 2024 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD”) (CSE:IDK / OTCQX:IDKFF) a Canadian based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, announces that through a series of recent transactions (“Dispositions”), ThreeD disposed of ownership and control of an aggregate of 5,159,000 common shares (the “Subject Shares”) of infinitii ai inc. (the “Company” or “infinitii”). As a result of the Dispositions, the percentage ownership held by ThreeD and Sheldon Inwentash (the “Joint Actor”) decreased by 4.1% from the last early warning report filed in connection with the acquisition of infinitii securities, from which ThreeD, along with the Joint actor, reported as 25.9% ownership on a partially diluted basis, assuming the exercise...

Final Short Form Prospectus Accessible on SEDAR+ Not for distribution to United States newswire services or dissemination in the United States ST. JOHN’S, Newfoundland, May 16, 2024 (GLOBE NEWSWIRE) — Kraken Robotics Inc. (“Kraken” or the “Company“) (TSX-V: PNG, OTCQB: KRKNF) announces that, further to its news release dated April 25, 2024, it has filed a final short form prospectus dated May 16, 2024 (the “Final Prospectus“) to qualify the distribution of 21,185,300 common shares (the “Common Shares“) from the treasury of the Company, at a price of $0.95 per Common Share for total gross proceeds of $20,126,035 (the “Offering“), which includes the 2,763,300 Common Shares being issued at a price of $0.95 per Common Share pursuant to the exercise in full by the underwriters...

DELTA, British Columbia, May 16, 2024 (GLOBE NEWSWIRE) — Swiss Water Decaffeinated Coffee Inc. (TSX– SWP) (“Swiss Water” or “the Company”) is pleased to announce the following voting results of the Company’s Annual General Meeting of Shareholders, which was held on Thursday, May 16, 2024. Election of Directors The Director nominees listed in the Management Information Circular for its Annual General Meeting of Shareholders were elected as Directors of Swiss Water. Voting results for individual Directors elected were as follows:  Votes For Votes AgainstNominee Number Percentage Number PercentageFrank A. Dennis 2,608,310 99.48%   13,692 0.52%  Roland W. Veit 2,604,587 99.34%   17,415 0.66%  Robert B. Johnston 2,601,550 99.22%   20,452 0.78%  Donald J. Tringali 2,603,050 99.28%   18,952 0.72%  Nancy L. McKenzie 2,604,447 99.33%   17,555 0.67%  Alan...